{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000525","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.607480+00:00","generated_at":"2026-05-24T06:09:15.038544+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty","bullets":["Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.","Consideration: 1M restricted shares (~16% dilution) plus 10% net sales revenue.","Term perpetual; if <$1.5M sales by Dec 2026, rights become non-exclusive; can extend 12 mo with $5M payment.","Raised $200k via sale of 80k shares at $2.50/share to accredited investor.","Clinical study: 14.3% reached HbA1c targets (vs 0% placebo); 83.3% reached SBP goals (vs 60%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000525","json":"https://secwatch.observer/filing/0001641172-25-000525.json","markdown":"https://secwatch.observer/filing/0001641172-25-000525.md","text":"https://secwatch.observer/filing/0001641172-25-000525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/0001641172-25-000525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:09:15.038544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}